ImmunityBio Seeks ANKTIVA Label Expansion for NMIBC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- FDA Review Progress: The U.S. FDA has accepted ImmunityBio's supplemental Biologics License Application (sBLA) for ANKTIVA, aiming to expand its indication to include patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), with a decision expected by January 6, 2027, which could significantly increase treatment options.
- Clinical Data Support: The sBLA submission is based on data from the QUILT-3.032 trial, showing a 12-month disease-free survival rate of 58.2% in 80 high-risk patients treated with ANKTIVA plus BCG, providing scientific justification for the indication expansion that may improve patient outcomes.
- Expert Consensus Reinforcement: At the FDA workshop in May 2026, experts unanimously agreed that CIS and papillary disease are biologically the same, supporting the inclusion of papillary disease in existing treatment protocols, highlighting the urgent treatment needs for BCG-unresponsive patients and furthering the sBLA review.
- Significant Market Potential: The expanded indication for ANKTIVA positions it as a crucial immunotherapy option for BCG-unresponsive patients, likely enhancing ImmunityBio's competitiveness in the bladder cancer treatment market and addressing the urgent needs of approximately 64,000 NMIBC patients diagnosed annually.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's ANKTIVA Therapy Economic Analysis Reveals Significant Cost Savings
- Significant Cost Savings: ImmunityBio's analysis indicates that ANKTIVA plus BCG can save up to $151,438 per cystectomy avoided in a U.S. Medicare population, highlighting the therapy's potential to reduce healthcare expenditures.
- Comparative Efficacy Advantage: The complete response rate for ANKTIVA plus BCG stands at 49.6%, surpassing TAR-200's 45.9%, while also incurring lower treatment and administration costs, showcasing ANKTIVA's competitive edge in treating BCG-unresponsive NMIBC patients.
- Economic Model Support: The findings are derived from a cost-consequence model utilizing data from ImmunityBio's QUILT-3.032 study and TAR-200's SunRISe-1 trial, emphasizing the potential of ANKTIVA plus BCG to deliver durable responses while lowering costs to the healthcare system.
- Optimistic Investor Sentiment: ImmunityBio's stock has surged 291% year-to-date and 192% over the past 12 months, reflecting a positive investor reaction to the economic analysis results and indicating strong market confidence in the company's future growth.
See More
Study Reveals Treatment Preferences in High-Risk Bladder Cancer Patients
- Diverse Patient Preferences: A study involving 86 UK patients with high-risk non-muscle-invasive bladder cancer (NMIBC) reveals that treatment preferences are highly individualized, shaped by personal experiences, values, and age, underscoring the importance of personalized care.
- Impact of BCG Treatment: Patients currently receiving BCG are more likely to favor bladder-sparing strategies, while those who have undergone radical cystectomy are more supportive of repeating that decision, reflecting the complexity and individual differences in treatment choices.
- Quality of Life Considerations: The study indicates significant variations in lifestyle disruption and quality-of-life considerations among patients, with male participants expressing greater concern about the daily-life impact of radical cystectomy, suggesting that medical decisions must integrate patient quality of life.
- Clinical Effectiveness Priority: Clinical effectiveness, including impacts on recurrence, progression, and life expectancy, is identified as the most critical factor influencing treatment decisions, demonstrating patients' trade-offs between cancer control and quality of life in their treatment choices.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: ImmunityBio, Inc. (NASDAQ: IBRX) faces a class action lawsuit for purchasers of its securities between January 19 and March 24, 2026, with a deadline of May 26, 2026, to apply as lead plaintiff, alleging violations of the Securities Exchange Act of 1934 by the company and its Executive Chairman.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements during the class period, particularly regarding its lead biologics product Anktiva, asserting it could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated.
- FDA Warning Letter Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock highlighted misleading advertising for Anktiva, resulting in a 21% drop in stock price, indicating a significant loss of market confidence in the company.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strong capabilities and influence in securities class action lawsuits.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased ImmunityBio securities between January 19 and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status in a class action lawsuit, indicating significant investor concern over potential misconduct by the company.
- Allegations Overview: The lawsuit alleges that ImmunityBio and its Executive Chairman made false or misleading statements during the class period, claiming that their lead product Anktiva could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, potentially undermining investor confidence.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to ImmunityBio's CEO highlighted misleading advertising of Anktiva, resulting in a 21% drop in stock price following the news, reflecting market apprehension regarding the company's compliance and regulatory standing.
- Law Firm Credentials: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its significant strength and influence in the securities class action landscape.
See More
Multiple Companies Facing Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations during the class period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from May 7, 2025, to February 4, 2026, of not disclosing underperformance in its Consumer Beauty segment and compressed margins due to increased marketing investments, which misled investors about the company's prospects.
- Super Micro Compliance Violations: Super Micro Computer is facing allegations from February 2, 2024, to March 19, 2026, for selling servers to Chinese companies, violating U.S. export control laws, which could expose the company to regulatory scrutiny.
- ImmunityBio Capability Overstatement: ImmunityBio is accused during the class period from January 19, 2026, to March 24, 2026, of overstating Anktiva's capabilities, leading to materially misleading statements about the company's business and operations, affecting investor confidence.
See More
ImmunityBio Securities Class Action Reminder
- Deadline for Claims: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: ImmunityBio and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to significant financial losses for investors.
- FDA Warning Impact: A warning letter from the FDA, made public on March 24, 2026, highlighted misleading advertisements for Anktiva, indicating violations of the Federal Food, Drug, and Cosmetic Act, raising public health concerns.
- Stock Price Volatility: Following the news, ImmunityBio's stock price plummeted by 21%, losing $1.98 per share to close at $7.42, reflecting market apprehension regarding the company's compliance and future outlook.
See More
ImmunityBio's ANKTIVA Therapy Economic Analysis Reveals Significant Cost Savings
- Significant Cost Savings: ImmunityBio's analysis indicates that ANKTIVA plus BCG can save up to $151,438 per cystectomy avoided in a U.S. Medicare population, highlighting the therapy's potential to reduce healthcare expenditures.
- Comparative Efficacy Advantage: The complete response rate for ANKTIVA plus BCG stands at 49.6%, surpassing TAR-200's 45.9%, while also incurring lower treatment and administration costs, showcasing ANKTIVA's competitive edge in treating BCG-unresponsive NMIBC patients.
- Economic Model Support: The findings are derived from a cost-consequence model utilizing data from ImmunityBio's QUILT-3.032 study and TAR-200's SunRISe-1 trial, emphasizing the potential of ANKTIVA plus BCG to deliver durable responses while lowering costs to the healthcare system.
- Optimistic Investor Sentiment: ImmunityBio's stock has surged 291% year-to-date and 192% over the past 12 months, reflecting a positive investor reaction to the economic analysis results and indicating strong market confidence in the company's future growth.
See More
Study Reveals Treatment Preferences in High-Risk Bladder Cancer Patients
- Diverse Patient Preferences: A study involving 86 UK patients with high-risk non-muscle-invasive bladder cancer (NMIBC) reveals that treatment preferences are highly individualized, shaped by personal experiences, values, and age, underscoring the importance of personalized care.
- Impact of BCG Treatment: Patients currently receiving BCG are more likely to favor bladder-sparing strategies, while those who have undergone radical cystectomy are more supportive of repeating that decision, reflecting the complexity and individual differences in treatment choices.
- Quality of Life Considerations: The study indicates significant variations in lifestyle disruption and quality-of-life considerations among patients, with male participants expressing greater concern about the daily-life impact of radical cystectomy, suggesting that medical decisions must integrate patient quality of life.
- Clinical Effectiveness Priority: Clinical effectiveness, including impacts on recurrence, progression, and life expectancy, is identified as the most critical factor influencing treatment decisions, demonstrating patients' trade-offs between cancer control and quality of life in their treatment choices.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: ImmunityBio, Inc. (NASDAQ: IBRX) faces a class action lawsuit for purchasers of its securities between January 19 and March 24, 2026, with a deadline of May 26, 2026, to apply as lead plaintiff, alleging violations of the Securities Exchange Act of 1934 by the company and its Executive Chairman.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements during the class period, particularly regarding its lead biologics product Anktiva, asserting it could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated.
- FDA Warning Letter Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock highlighted misleading advertising for Anktiva, resulting in a 21% drop in stock price, indicating a significant loss of market confidence in the company.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strong capabilities and influence in securities class action lawsuits.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased ImmunityBio securities between January 19 and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status in a class action lawsuit, indicating significant investor concern over potential misconduct by the company.
- Allegations Overview: The lawsuit alleges that ImmunityBio and its Executive Chairman made false or misleading statements during the class period, claiming that their lead product Anktiva could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, potentially undermining investor confidence.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to ImmunityBio's CEO highlighted misleading advertising of Anktiva, resulting in a 21% drop in stock price following the news, reflecting market apprehension regarding the company's compliance and regulatory standing.
- Law Firm Credentials: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its significant strength and influence in the securities class action landscape.
See More
Multiple Companies Facing Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations during the class period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from May 7, 2025, to February 4, 2026, of not disclosing underperformance in its Consumer Beauty segment and compressed margins due to increased marketing investments, which misled investors about the company's prospects.
- Super Micro Compliance Violations: Super Micro Computer is facing allegations from February 2, 2024, to March 19, 2026, for selling servers to Chinese companies, violating U.S. export control laws, which could expose the company to regulatory scrutiny.
- ImmunityBio Capability Overstatement: ImmunityBio is accused during the class period from January 19, 2026, to March 24, 2026, of overstating Anktiva's capabilities, leading to materially misleading statements about the company's business and operations, affecting investor confidence.
See More
ImmunityBio Securities Class Action Reminder
- Deadline for Claims: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: ImmunityBio and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to significant financial losses for investors.
- FDA Warning Impact: A warning letter from the FDA, made public on March 24, 2026, highlighted misleading advertisements for Anktiva, indicating violations of the Federal Food, Drug, and Cosmetic Act, raising public health concerns.
- Stock Price Volatility: Following the news, ImmunityBio's stock price plummeted by 21%, losing $1.98 per share to close at $7.42, reflecting market apprehension regarding the company's compliance and future outlook.
See More
